NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board.

Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University. Dr. Gabelle is also researcher at the Montpellier Institute of Neurosciences and member of the European Alzheimer’s Disease Consortium.

credit to JR2245, stocktwits
"$AVXL Audrey Gabelle just made a good post on LinkedIn. Her quote about Anavex is as follows: "💊 I had the honor of presenting the concrete and innovative therapeutic promises of hashtag#Blarcamésine, Anavex Life Sciences new oral treatment objectifying positive 👏clinical, functional and biomarker effects at 48 weeks, confirmed at 192 weeks during the open-label study (ATTENTION-AD) against Alzheimer's disease. "

Thank you, georgejjl, for your DD and valuable contribution to this community!

By Bio-Fried on stocktwits:
$AVXL Great news:

The meeting in question involved representatives from Anavex Life Sciences Corp., including a woman named Neil, and U.S. Congressman Henry Cuellar of Texas. This meeting took place in Congressman Cuellar’s office in Washington, D.C., and was focused on discussing Anavex’s ongoing work in neurodegenerative disease research, particularly related to Alzheimer’s disease. ?

Congressman Cuellar shared details of this meeting on his official X (formerly Twitter) account, stating:

“After wrapping up a full night of voting at 7am, I was pleased to meet with @AnavexLifeSci this morning to learn more about their work on Alzheimer’s disease research.”

I've been distressed by recent reports showing Starr County has one of the highest dementia rates in the country. In the face of such challenges, advancing medical treatments is essential to protecting the health of our communities. I’ll always support research and innovation in Congress.
Bullish

Peer Review is a STAMP of APPROVAL of Trial Results. and although is "not an endorsement" for EMA approval,
but most of the signatories and co-authors of the paper are European Scientists! And it means a lot!
BTW, does anybody remember when mabs trial have been positively covered in scientific community?
So, the FUD spread here is just a noise helping short trading...

Great Post, Steady_T,
It breaks all negative narratives posted by FUD crew.
THANKS!

keyeaster on stocktwits:
10:39 AM

$AVXL I made an interesting observation from the FAAST conference programme in Paris on June 5. Blarcamesine is the only "treatment" being presented: "GABELLE Audrey (CHU de Montpellier, Montpellier)
Blarcamesine: a new oral treatment for Alzheimer's disease." faast.sciencesconf.org/

France Alzheimer - Actualité Scientifiques et Thérapeutiques - Sciencesconf.org

https://faast.sciencesconf.org




33

credit to Factanonverba, stocktwits, 11:51 AM

$AVXL New mention in International Journal of Molecular Sciences. "Blarcamesine, an oral small molecule agonist targeting the Sigma-1 receptor, is effective in improving the level of mitochondrial activation and ameliorating neuroinflammation in neuronal cells [206]."
mdpi.com/1422-0067/26/11/4974

need some help... How long clock stop lasts?
thank you!

Professor Gabelle:
“I’m thrilled to join Anavex’s Scientific Advisory Board given the convincing profile of blarcamesine as a potentially relevant treatment for patients with Alzheimer’s disease,” said Professor Dr. Gabelle. “There is a tremendous unmet medical need around the globe caused by Alzheimer’s disease. I look forward to collaborating on cutting-edge science and helping guide the development of new therapies that can make a meaningful impact on neurodegenerative disorders. A small molecule administered orally once daily, with demonstrated clinically meaningful improvement and good safety profile could be a game changer for patients, health care burden and equity of access to care. I am committed to leveraging my experience, and to supporting the Anavex Life Sciences Company’s ambition of improving lives through novel precision medicine such as blarcamesine.”

looks like the train is leaving the station...

22 April 2025
EMA/CHMP/112185/2025
Human Medicines Division
Committee for medicinal products for human use (CHMP)
Agenda for the meeting on 22-25 April 2025
Chair: Bruno Sepodes – Vice-Chair: Outi Mäki-Ikola
22 April 2025, 09:00 – 19:30, virtual meeting/room 1C
23 April 2025, 08:30 – 19:30, virtual meeting/room 1C
24 April 2025, 08:30 – 19:30, virtual meeting/room 1C
25 April 2025, 08:30 – 15:00, virtual meeting/room 1C
Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive
and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed
against products, it must be noted that these may not reflect the full wording proposed by applicants
and may also vary during the course of the review. Additional details on some of these procedures will
be published in the CHMP meeting highlights once the procedures are finalised and start of referrals
will also be available.
Of note, this agenda is a working document primarily designed for CHMP members and the work the
Committee undertakes.
Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for
access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when
adopted or considered public according to the principles stated in the Agency policy on access to
documents (EMA/127362/2006).

Agree, 100%!

Alzheimer Europe:
https://www.alzheimer-europe.org/news/anavex-presents-results-phase-2b/3-open-label-extension-trial-early-ad

Here is an excerpt from Dr. Marwan Sabbagh rebuttal to Jesse Brodkin Email to JPAD:
""In summary, all questions have been answered and have no scientific merit. Again, this Letter to the Editor follows the same pattern as the previous email inquiries sent by Jesse Brodkin to disparage the Sponsor and JPAD. Specifically, hedge funds target companies to disparage them and their scientific work within respected papers in order to gain financially by shorting them, which is illegal and criminal."
Why Jesse Brodkin sent his 'inspirational' email to JPAD? Money? I think so. Reminds me some of continued efforts by some
'EXPERTS' on this board for years spreading FUD. And yes, it could work until Peer Review was published and cleared the smoke of lies. The continued effort to 'disparage sponsor' just shows the criminal motives of those bashers! Who is Doc28?
What is his background to give 4 % chances of approval? And what about hard working 'INVESTOR' with his negative spin
on every good news from the company? IMO, every true scientist would/should respect the study and conclusion of Peer Review Scientists and wait at least until the EMA decision...But AVXL stock still needs to be manipulated and that's what we have. Trust the COMPANY, not the 'DOCS' behind the computer screens!
AVXL is the best AD treatment option currently and the stakes are high.

IMHO, Dr. Sabbagh's rebuttal to Dr. Brodkin's letter to JPAD letter not only shredded into pieces
Brodkin's attempt to discredit AVXL AD trial results, but also draws a parallel , or if you want, similarities to negative narratives and spinning on this and other boards. That right, some iHub 'expert' tried to spread FUD and post negative spin to any good news released by the company. IMO, those 'experts could be part of collusive conspiracy as Dr. Brodkin is, to influence trading activity helping shorts, MMs and other 'AVXL' friends to cap the stock price at these levels. Fortunately, educated longs know where this saga heading up how it should end.

When is the Middle Est AD conference? anybody, thanks

Yes, some FUD spreading posters (you know who they are) obviously having BIO background, but also seem not to being currently employed buy any lab or university: too much time spending on this board. But those clowns show strong dedication to support short thesis, helping MMs, hedge funds and COMPETITION to manipulate the stock price.
Remember, Jesse's analytics gives investors an idea where could be stock price upon EMA approval!

Just wondering, who would trust some of FUD spreading posters on this board for years hanging on this board and claiming now that AVXL has 4% chance of approval? And this is in light of Peer Review stamp of approval of trial results by real and World Renown Scientists. I think that people here should understand that those FUDsters should be hedgiest, or MMs trolls.

IMO, the stock price at this time has no difference, unless you are a trader. For longs it offers an opportunity to buy at this low and when approval comes multiply many times your investment...
Good luck to all!

Regardless what bashers on this board say, and what market does with current price, here is what one smart poster put on ST: "

kay91667
Yesterday 9:27 PM

$AVXL *Large-Scale Scientific Endorsement is Rare
- Having 58 neuroscientists co-sign a study suggests broad scientific support, which is not typical in drug development.
Most peer-reviewed studies have a handful of authors, usually from the same research team or institution.
A large number of independent experts supporting a drug implies a strong consensus on its potential.
*Significance for EMA Approval
-Broad Scientific Endorsement (58 neuroscientists): The large number of co-authors suggests strong academic backing, which can be influential during the regulatory review process. It may signal to the EMA that the drug has significant scientific merit and that the findings are supported by a broad group of experts.
Scientific Consensus: The fact that 58 neuroscientists support the study indicates that multiple independent experts in the field consider the findings important and potentially groundbreaking, which could strengthen the case for regulatory approval.
Bullish "

Bravo!

Hi George, maybe not a mistake... Why would anybody put a negative spin on any good news coming from AVXL?
Mission Impossible? BTW, some of those contrast liquids are causing negative effect on kidneys. It would be nice, if 'Doc' mentioned it in his FUD post...
BTW, thank you for shared DD on IH and other boards!
All these negative, so called 'experts', have no shame by not showing respect for the real scientists and real EXPERTS (Including World Authorities in the FIELD) that co-signed Peer Review Paper!

Hi rx7171, let's look at the at the deal regarding 20% partnership. As I read about, the industry acceptable terms 15-30 %. Just for the argument's sake, our partner for the 80% provides Blarca Manufacturing, Marketing, Sales and Distibution. And the net profit might be in the range of 20% of revenues. For AVXL, 20%.of sales go strait to the bottom line. The partner (BP) has resources to ramp up sales, by established sales force, provide TV ADS and other
other media channels. AVXl could concentrate on other clinical trials growing its future business. Another advantage to partner might be positive influence
on regulatory agencies and the market too.
At this time so many unknowns:
- we don't know the partnership terms, assuming 80-20%
- blarca annual price, assuming $6000
- ramp up of sales speed, assuming that
one year from the day of approval, 2 million will be receiving blarca. of course, it will start slow, but the market will value sales using 2 million, IMHO.
so, let's assume that the market could use the following revenue/stock pricing model:
$ 6000 * 2,000.000 (patients) = 12 billions of revenues. AVXL gets 2.4 billion. Operating expense (new trials, increased payroll, etc..) 300 million.
First profitable year - no taxes. 2.1 billion divide over 90 million shares = EPS 23 apply PE of 15,20,25,30,etc
I do not think anybody would campaign about the price at this time and HUGE future potential.
That is why the stock price depressed, under short covering and accumulation right now. Approval by EMA and volcano erupts!

D-Mike, something like this could happen and will, IMHO. Although AVXL had several milestone news/events and stock should be already trading in $30-35 range. Looks like the MARKET tries to hold AVXL at this junction, allowing short covering and accumulation. EMA approval will be Earth Shuttering Event in CNS
and the entire market, turning million of heads toward AVXL, its pipeline and technology. And even in early months after approval with first Q profit, market will
award high PE and AVXL will be trading in high numbers. AVXL will partner.
Three factors will most likely determine the stock price, IMHO:
- Anavex's share of gross sales. Usually, it is 20% (but I could be wrong...).
- Drug price. If it will be half of MABs, WE, investors, will be golden
- Number of patients increase worldwide and consequently revenues increase from Q to Q. With a right partner it should happen.

I think upon approval, AVXL should move very fast toward $200 range and then who know... I think the numbers posted by MayoMobile are realistic.
Thank you, Jesse for your invaluable contribution!!!
Also, I want to express my (and I think other shareholders/investors) appreciation for your help to understand AVXL tech and chances of succeeding in bringing it to the market.
SK

https://usawire.com/christopher-missling-phd-and-anavex-life-sciences-pioneering-precision-medicine-for-cns-disorders/amp/
Sorry if it was posted... I think that Asad Azeem, the author, should with kund first before positive valuation of CM for AVXL the neuro field...

He is here to bash and spread FUD and always was...

Thank you, williamssc!

xodcode, after Peer Review all doubts and all other typical negative spin narratives have been answered and dismissed.
Yes, the MARKET has its goal/agenda regarding the stock price. It could be short covering, accumulation, or both. We have posters on this board
with background in BIO and pharmaceuticals that have been bringing some light on the technology and trial results, some having some doubts on the trials.
success, CM leadership, etc... There have been some pitfalls with the timelines, trial design (not on AD) etc.
But we got game changing Peer Review that rubber stamped AVXL success!
Kund, who is this nobody poster? He is a resident basher (actually not smart as others) spreading stupid FUD and most likely getting paid for his dirty job.
After EMA Acceptance and Peer Review every 'expert' should wait until EMA decision, I think... And if some 'experts' continue spreading FUD, it just means that they just doing their part in helping manipulate the stock price.
We know, the MARKET mostly has been
unfriendly to AVXL for a reason: BIG money on the line with a potential to be lost by that competition. So, the fight is still on.
I think, from these levels AVXL can easy go to at least $200 and up...Our day is coming, just a matter of time with NEW HHS Secretary and FDA Chief.
Go AVXL!
BTW, thank you for your contribution!

the fourth one - is patience...

Good news for AVXL! Hopefully the change at the FDA will move swiftly and in our favor.
Thank you!

Brian5220 from ST 22 PM

$AVXL During todays Senate confirmation hearing for RFK Jr. as HHS Secretary, Kennedy stated, paraphrased here, " We have wasted a lot of time on false studies for Alzheimer's treatments when there are new studies available". Sounds like he would be open to new treatments. 👍
Bullish

Probably CM already knew it, when he mentioned "the pic of the iceberg".
Thanks, baltimorebullet!.

another 'expert' opinion?

"blarcamesine has proven through nine years of drug trial results, that it is the best drug to treat Alzheimer disease and should be the new SOC drug. Peer review results is the stamp of approval by the experts. Period!"
Bravo, bb8675309! - stamp of approval. The FUD has no shame.

That's right. I also curious to hear the answer,
I think inventing shortfalls of the trials, performants of blacamesine and typing messages to educate this board.

Really? Or this is just a sarcastic joke?

Obsoletely! Very good point!

Thanks, xodcode, agree with everything you said and have a comment regarding ChatGTP, that actually a computer software forming responses to queries and
its performants depend on the information stored in the related database, which in turn depends on timely updates. This is my way to see it, having IT experience.
I think that Peer Review is the ultimate authority in neurology and naturally overwaits all other opponents. I'm sure, EMA will reference the Article and its decision
will be grossly influences by Peer Review, leading to approval! In my book - 99% probability.
As to the stock price upon approval, it will eventually be heading in the direction suggested by MayoMobile (Jesse), where he was using different scenarios and factors, including treatment price, partnership terms and some other conditions.
And we should not forget the entire pipeline of upcoming trials and potential treatments...
I also want to mention that your valuable and truthful posts are a huge contribution to this community. Thank you for that!
Best Regards,
Sam

Graniteguy, I agree with you. There are a few characters like him, including investors24, on this board that now looking laughable and remind Don Quixote
fighting windmills (from Miguel de Servantis novel). They showed their true colors by opposing Peer Review signed by 58 neurologists, including world authorities in the field, and now appearing as FUDsters working for some sponsors. I think they not voicing their opinion but are part of criminal conspiracy and fraudulent market manipulation. When MARKET (MMs, funds, institutions) is ready and loaded, the stock will go to the Moon